Cancer Patients Receive Nano-engineered Therapy

Unlike other approaches, this microparticle is being applied directly to the tumor, where it is expected to regress the tumor with minimal damage to healthy tissues. The study is being conducted at the Singapore General Hospital.

"This represents an important milestone, we have been working to this goal for the past two years. We hope to inform the [public] of the performance of BrachySil by the end of October 2004, reported Gavin Rezos, managing director, pSivida.


Related Links:
PSivida